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We evaluated the individual and combined levels of urine dipstick and total lymphocyte count (TLC) as surrogate markers
for CD4 count in a low-resource community in Ghana. This cross-sectional study recruited 200 HIV-infected patients from
the Saint Francis Xavier Hospital, Assin Fosu, Ghana. Complete blood count, CD4 count, and urine dipstick analysis were
measured for participants. The threshold values were determined as <350 cells/μl for CD4, <1200 cells/μl for TLC, and
≥+ on urine dipstick analysis. The mean age of participants was 43.09 years. Proteinuria ≥ + [aOR = 4.30 (3.0–18.5)],
leukocyturia ≥ + [aOR = 2.91 (1.33–12.5)], hematuria ≥ + [aOR = 2.30 (1.08–9.64)], and TLC < 1200 cells/μl [aOR = 3.26
(3.94–15.29)] were signiﬁcantly associated with increased risk of CD4 count < 350 cells/μl. Using the individual markers,
the best substitute marker for predicting CD4 count < 350 cells/μl was proteinuria at a cutoﬀ point ≥ 2++, AUC of 0.973,
sensitivity of 97.6%, speciﬁcity of 100.0%, PPV of 100.0%, and NPV of 89.1%. A combination of ≤ 1200 TLC + ≥ 2++
(leukocyturia + proteinuria + hematuria) yielded an AUC of 0.980, sensitivity (72.8%), speciﬁcity (100.0%), PPV (100.0%), and
NPV (97.9%). Proteinuria could serve as a noninvasive screening tool, but the combination of proteinuria, leukocyturia,
hematuria, and TLC serves as a better substitute marker for CD4 count in monitoring the disease progression among HIV
patients in low-resource communities.

1. Background
Human immunodeﬁciency virus (HIV) remains a public
health burden in both developed and underdeveloped
countries [1]. Globally, 37 million people are living with
HIV, out of which about 26 million of them reside in
sub-Saharan Africa [2]. In Ghana, the prevalence of HIV
among adult aged 15–49 years old has declined from
about 2.4% in 2013 to about 1.6% in 2015 [3]. The rapid

use of highly active antiretroviral therapy (HAART) in
the last eight years especially in developing countries has
yielded tremendous achievements and improvement of
CD4 counts of immune compromised individuals. The
previous guidelines recommended to start HAART for
HIV conﬁrmed individuals with CD4 count < 200 cells/μl.
The current improvements in diagnosis and treatments
have led to the development of a new treatment guideline
which recommends HAART for all conﬁrmed HIV
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individual with CD4 count 350 cells/μl to 500 cells/μl
depending on the clinical conditions and comorbidities
[4, 5]. Despite this achievement to treatment, most developing countries have inadequate facilities, inadequate
CD4 FASC count machines, inadequate human resources,
and insuﬃcient supply of CD4 count reagents [6]. In
addition to the aforementioned challenges, Ghana still
faces a huge ﬁnancial crisis needed to support HIV treatment and repair broken-down FASC count machine [7].
For the reason that Ghana has not yet implemented the
latest WHO guidelines, means implementing it is likely
to increase enrolment of participants for HAART and
also worsen the challenges faced by the low-resource
communities [8].
The WHO recommendation that ART should commence for all HIV-conﬁrmed individuals in clinical stages
II or III with total lymphocyte count (TLC) < 1200 cell/μl
was also in recognition to the challenges faced by lowresourced communities [9]. Following this initiation, some
studies have found a signiﬁcant correlation between CD4
count and TLC [10–12]. The use of TLC yielded a high sensitivity and speciﬁcity in predicting CD4 count < 200 cell/μl
among HIV-conﬁrmed patients living in Ghana [13] and
Ethiopia [14]. However, other studies by Daka et al. [12]
and Akinola et al. [15] found TLC as a poor diagnostic
marker and hence could not recommend it as a substitute
for CD4 count. To overcome this limitation, some studies
explored the diagnostic performance of TLC in combination with other less expensive parameters such as hemoglobin, hematocrit, BMI, and erythrocyte sedimentation
rate (ESR) [11, 16]. These studies observed a better sensitivity and speciﬁcity of the combined markers for predicting CD4 count < 200 cell/μl compared to using the
individual markers alone. Although, most of the markers
used in the latter studies were less expensive, they
required adequate expertise and extensive electricity
power supply. Hence, there is a need to develop a much
lesser expensive marker as a substitute for CD4 count in
these settings [17].
Noninvasive markers of dipstick urine abnormality
ﬁndings such as proteinuria, leukocyturia, and hematuria
were found to be signiﬁcantly associated with a declined
CD4 count [18]. To date, very few studies have attempted
to conﬁrm this ﬁnding. Whether the diagnostic performance of the dipstick urinalysis ﬁndings will be a useful
substitute marker for CD4 count in a low-resource setting
like Ghana is yet to be explored. Very little or no research
has been conducted in Ghana among HIV-infected
HAART naive individual after the implementation of the
latest WHO cutoﬀ point to start HAART. It is against this
background that this study evaluated the individual and
combined markers of urine dipstick ﬁndings and TLC as
substitute markers for CD4 count < 350 cell/μl in Ghana.
Dipstick urinalysis is less expensive and will develop innovative approach to diagnosis and treatments, which will

further facilitate implementation of the latest WHO treatment guideline.

2. Materials and Methods
2.1. Study Design, Period, and Setting. This was a hospitalbased cross-sectional study carried out at the HIV Clinic
of Saint Francis Xavier Hospital, Assin Fosu, in the Central Region of Ghana from August 2016 to May 2017. Saint
Francis Xavier Hospital, Assin Fosu, is the largest hospital
in the central region of Ghana with a 118 bed capacity and
is a major referral centre that provides health services to
patients from a catchment area population of 207,000 in
Ghana [19].
2.2. Study Participants. Two hundred (200) newly diagnosed
HIV-infected patients between the ages of 15–64 years at the
HIV Clinic at Saint Francis Xavier Hospital were randomly
selected for the study. Patients under antiretroviral therapy,
pregnant women, and those with other medical conditions
such as sickle cell disease, viral hepatitis B or C, diabetes mellitus, systemic lupus erythematosus, tuberculosis and acute
viral infections, joint inﬂammatory diseases, sign of urinary
tract infections were excluded from the study. Other signs
of active infections and conditions that may interfere with
urine dipstick analysis or kidney function test were also
excluded. A questionnaire was used to collect sociodemographic characteristics of the study participants. Other vital
information pertaining to the clinical history of all participants was obtained from the hospital’s data review records
for each patient.
2.3. Ethical Consideration. This study was approved by the
Committee on Human Research Publications and Ethics
(CHRPE) at the School of Medical Sciences, Kwame Nkrumah University of Science and Technology and the Ethical
Committee of the at Saint Francis Xavier Hospital. Participation was voluntary and written informed consent was
obtained from each participant. All information obtained
from participants were kept under strict conﬁdentiality.
2.4. Blood Collection, Total Lymphocyte, and CD4 Counts. A
volume of 5 mL of venous blood was taken from the subjects
via phlebotomy and transferred into vacutainer tubes with
ethylenediaminetetraacetic acid (EDTA). Samples from the
subjects were analysed within 2 to 4 hours of collection.
The EDTA blood sample was used for the measurement of
CD4 cell count and complete blood count (CBC). FBC was
analysed using a ﬁve-diﬀerential automated blood analyzer
(HORIBA Yumizen H500, Horiba Medical, Japan) and
CD4 T lymphocyte count was determined using the Becton
Dickinson (BD) FASCount system (Becton, Dickinson and
Company, CA, USA). The BD FASCount system uses ﬂow
cytometry for the quantiﬁcation of the CD4 T lymphocytes.
Total lymphocyte count was determined and expressed
in cells/μl as follows:

White blood cell WBC × 1000 × percentage lymphocyte expressed as decimals
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Table 1: General characteristics of study participants.
Characteristics
Age (year)
15–24
25–34
35–44
45–54
55–64
Gender
Male
Female
Marital status
Single
Married
Divorced

Frequency

Percentages

10
47
68
47
28

5.0
23.5
34.0
23.5
14.0

57
143

28.5
71.5

53
35
112

26.5
17.5
56.0

2.5. Urine Collection and Biochemical Analysis. About 10–20
millilitres of early morning midstream urine were collected
from each participant into a clean leak-proof container for
analysis. Dipstick urinalysis strips (Accu-Tell Ref ABTUM-A33) were used to detect the following parameters in
urine provided by the participants: protein, glucose, bilirubin, urobilinogen, ketones, blood, and leukocytes.
2.6. Statistical Analysis. The data collected was entered into
Microsoft Excel and analyzed with SPSS version 23. The basic
characteristics were presented as means and standard deviations (SD) for continuous data and as frequencies for categorical data. Comparisons between male and female were
made using independent Student’s t-tests for continuous data
and chi-square tests for categorical data. Receiver operating
characteristic (ROC) curves were used to demonstrate the
individual and combined diagnostic performance of selected
urine dipstick biochemistry and TLC as alternative markers
for CD4 count. Sensitivity, speciﬁcity, and positive and
negative predictive values were reported. Logistic regression analysis adjusting for signs of active infections and
conditions that may interfere with urine dipstick analysis
was performed to predict urine dipstick biochemistry and
TLC associated with CD4 counts. The level of signiﬁcance
was set at p < 0 05 for all statistical comparisons.

3. Results
The mean age of participants was 43.09 years, and the most
frequently represented age group was 35–44 years (34.0%).
There was no signiﬁcant diﬀerence between the mean ages
of males and females. There were more female participants
(71.5%) than males (28.5%) and a higher proportion of the
participants were divorced (56.0%) (Table 1).
As shown in Table 2, the general prevalence of leukocyturia, proteinuria, and hematuria was 50.0%, 54.5%, and
51.5%, respectively. There was no signiﬁcant diﬀerence in
proportion between males and females in terms of the
presence and absence of leukocyturia (p = 0 3105), proteinuria
(p = 0 8871), and hematuria (p = 0 2121). Additionally, no

signiﬁcant diﬀerence was observed between males and females
in terms of the mean concentration of CD4 (p = 0 1109),
TLC (p = 0 4017), Hb (p = 0 1992), and WBC (p = 0 3629).
There was a signiﬁcant association of CD4 count with
leukocyturia (p < 0 0001), proteinuria (p < 0 0001), hematuria (p < 0 0001), and TLC (p < 0 0001). Individuals with proteinuria (≥+), leukocyturia (≥+), hematuria (≥+), and TLC
(<1200 cells/μl) were signiﬁcantly associated with 4.30 times,
2.91 times, 2.30 times, and 3.26 times increased risk of CD4
count < 350 cells/μl, respectively, (Table 3).
Using various threshold points, the best cutoﬀ point
for leukocyturia was ≥2++ with sensitivity of 92.1%, speciﬁcity of 98.9%, positive predicted values (PPV) of 100.0%,
and negative predicted value (NPV) of 83.3% for predicting CD4 count < 350 cells/μl. The best threshold point
for proteinuria was ≥2++ with sensitivity of 97.6%, speciﬁcity of 100.0%, PPV of 100.0%, and NPV of 89.1% for
predicting CD4 count <350 cells/μl. The best threshold
point for hematuria was ≥2++ with sensitivity of 92.7%,
speciﬁcity of 98.6%, PPV of 100.0%, and NPV of 83.7%
for predicting CD4 count < 350 cells/μl. TLC of <1200
was shown to have a sensitivity of 85.1%, speciﬁcity of
100.0%, PPV of 100.0%, and NPV of 88.9% for predicting
CD4 count < 350 cells/μl. The best area under the curve
(AUC) was identiﬁed for proteinuria ≥ 2++ (AUC = 0.973)
followed by TLC (AUC = 0.940), hematuria (AUC = 0.938),
and leukocyturia (AUC = 0.901). The closeness of the AUC
for proteinuria to “1.0” makes it a better diagnostic tool for
predicting CD4 < 350 cell/μl, hence making it a better alternative marker for CD4 count (Table 4).
As shown in Table 5, using the best threshold
points <1200 cell/μl for TLC, ≥2++ for proteinuria, ≥2++
for leukocyturia, and ≥2++ for hematuria, a sensitivity of
72.8%, speciﬁcity of 100.0%, PPV of 100.0%, and NPV of
97.9% was found to predict CD4 count <350 cells/μl among
HIV-infected participants.
A shown in Figure 1, a higher AUC of 0.980 was
observed for the combination of the signiﬁcant threshold
point for TLC, proteinuria, leukocyturia, and hematuria
making the combined markers a perfect alternative marker
for CD4 count.

4. Discussion
This study evaluated the individual and combined diagnostic
performances of some selected measures of dipstick urinalysis and total lymphocyte count as alternative markers for
CD4 count in low-resource communities in Ghana.
Based on our result, there was a signiﬁcantly high proportion of hematuria, proteinuria, and leukocyturia among HIVinfected participants with a declined CD4 count. Signiﬁcantly
high counts of proteinuria, leukocyturia, and hematuria
were independent risk factors for CD4 count < 350 cell/μl.
A cross-sectional study conducted by FolefackKaze et al.
[20] among HIV-infected patients in Cameroon found signiﬁcant associations of proteinuria, hematuria, and leukocyturia with a declined CD4 count, which is consistent
with the ﬁndings in our study. The prevalence of proteinuria observed in this present study was signiﬁcantly higher
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Table 2: Urine dipstick biochemistry and CD4, TLC, Hb, and WBC categorized by sex.

Characteristics
b

Mean age
Leucocytesa
Absent
1+
2++
3+++
Leukocyturia
Proteina
Absent
1+
2++
3+++
Proteinuria
Blooda
Absent
1+
2++
3+++
Hematuria
Mean CD4 (cell/μl)b
Mean TLC (cell/μl)b
Mean HB (g/dl)b
Mean WBC (×109)b

Total (n = 200)

Male (n = 57)

Female (n = 143)

43.09 ± 10.33

43.44 ± 9.9

42.74 ± 10.76

100 (50.0%)
28 (28.0%)
48 (48.0%)
24 (24.0%)
100 (50.0%)

23 (40.3%)
9 (15.8%)
18 (31.6%)
7 (12.3%)
34 (34.0%)

77 (53.8%)
19 (13.3%)
30 (21.0%)
17 (11.9%)
66 (66.0%)

97 (48.5%)
27 (13.5%)
51 (25.5%)
25 (12.5%)
103 (51.5%)

27 (47.4%)
12 (21.1%)
13 (22.8%)
5 (8.8%)
30 (29.1%)

70 (48.9%)
15 (10.5%)
38 (26.6%)
20 (14.0%)
73 (70.9%)

91 (45.5%)
27 (13.5%)
57 (28.5%)
25 (12.5%)
109 (54.5%)
302.32 ± 32.4
1166.59 ± 73.7
7.32 ± 1.64
2.36 ± 0.47

25 (43.9%)
9 (15.7%)
15 (26.3%)
8 (14.0%)
32 (29.4%)
273.43 ± 26.8
1121.83 ± 90.32
7.12 ± 1.85
2.318 ± 0.51

X2, df

p value

3.580, 3

0.5315
0.3105

4.503, 3

0.2121

0.6404, 3

0.8871

66 (46.1%)
18 (12.6%)
42 (29.4%)
17 (11.9%)
77 (70.6%)
331.21 ± 38.0
1211.36 ± 57.18
7.52 ± 1.43
2.403 ± 0.44

0.1109
0.4017
0.1992
0.3629

Values are presented as mean ± SD and frequency (percentages). TLC: total lymphocyte count; Hb: hemoglobin; WBC: white blood cell. aChi-square test;
b
Student’s t-test.

Table 3: Association of CD4 count with urine dipstick biochemical analysis and TLC.
Characteristics
Leukocyturia
Absent
Present (≥+)
Proteinuria
Absent
Present (≥+)
Hematuria
Absent
Present (≥+)
TLC (cells/μl)
≤1200
>1200

Total

CD4 count staging

p value

<350

≥350

CD4 < 350 cells/μl
aOR (95%C1)

100
100

8 (9.9%)
73 (90.1%)

92 (77.3%)
27 (22.7%)

Reference
2.91(1.33 to 12.5)

<0.0001

91
109

1 (1.2%)
80 (98.8%)

90 (75.6%)
29 (24.4%)

Reference
4.30 (3.0 to 18.5)

<0.0001

97
103

10 (12.3%)
71 (87.6%)

87 (73.1%)
32 (26.9%)

107
93

69 (85.1%)
12 (14.8%)

38 (31.9%)
81 (68.1%)

Reference
2.30 (1.08 to 9.64)
Reference
3.26 (3.94 to 15.29)

<0.0001
<0.0001

aOR: adjusted odds ratio for signs of active infections and conditions that may interfere with urine dipstick analysis.

compared to the other urine abnormalities. This is consistent with previous reports that proteinuria is the leading
urinary abnormality associated with declined CD4 count
[20]. Therefore, renal insuﬃciency could be the underlining
cause of proteinuria arising from an advanced stage HIV
infection and a declined CD4 count [20–22]. Conversely,

some studies found no signiﬁcant association between renal
failure and a decline in CD4 count under routine clinical
management [23]. There is no clear mechanism linking a
declined CD4 count to the presence of hematuria in HIV
infection; however, this could be attributed to unforeseen
cofounders [24, 25].
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Table 4: Individual diagnostic performance of selected urine dipstick biochemistry and TLC as alternative markers for CD4 Count.
Markers

Sensitivity

Leukocyturia
≥1+
≥2++
≥3+++
Proteinuria
≥1+
≥2++
≥3+++
Hematuria
≥1+
≥2++
≥3+++
TLC (cell/μl)
<800
<1000
<1200
<1400

Speciﬁcity

PPV

NPV

AUC (p value)
0.901 (p < 0 0001)

90.1%
92.1%
68.3%

77.3%
98.9%
97.9%

92.0%
100.0%
88.70%

73.1%
83.3%
80.5%

87.6%
97.6%
73.0%

73.1%
100.0%
100.0%

89.7%
100.0%
99.8%

68.9%
89.1%
88.7%

98.7%
92.7%
89.8%

75.6%
98.6%
93.1%

98.9%
100.0%
91.0%

73.4%
83.7%
85.2%

76.3%
80.2%
85.1%
79.5%

68.1%
74.8%
100.0%
87.2%

82.9%
97.6%
100.0%
94.3%

78.0%
84.3%
88.9%
72.3%

0.973 (p < 0 0001)

0.938 (p < 0 0001)

0.940 (p < 0 0001)

Table 5: Combined diagnostic performance of urine dipstick biochemistry and TLC as alternative markers for CD4.
Markers
≤1200 TLC + leukocyturia ≥ 2++
≤1200 TLC + proteinuria ≥ 2++
≤1200 TLC + hematuria ≥ 2++
≤1200 TLC + ≥2++ (Leu + Pro + Hem)

Sensitivity

Speciﬁcity

PPV

NPV

AUC (p value)

76.2%
88.1%
83.3%
72.8%

100.0%
100.0%
100.0%
100.0%

100.0%
100.0%
100.0%
100.0%

87.3%
93.8%
89.2%
97.9%

0.937 (p < 0 0001)
0.978 (p < 0 0001)
0.960 (p < 0 0001)
0.980 (p < 0 0001)

Leu: leukocyturia; Pro: proteinuria; Hem: hematuria.

ROC curve/<1200 TLC + ≥ 2 (PRO + LEU + HEM)/AUC = 0.9805
1

True positive rate (sensitivity)

0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

0

0.2

0.4

0.6

0.8

1

False positive rate (1 − specificity)

Figure 1: Receiver operating characteristic (ROC) curve for
combined TLC, proteinuria, leukocyturia, and hematuria marker
for predicting <350cells/μl.

When TLC and the individual markers of dipstick urinalysis were explored for predicting CD4 count < 350 cells/μl,
proteinuria (at a cutoﬀ point ≥ 2++) was observed as the

best substitute for CD4 count with sensitivity of 97.6%,
speciﬁcity of 100.0%, PPV of 100.0%, and NPV of 89.1%.
Moreover, proteinuria when compared to TLC in this study
was found to be the second-best substitute marker with a
sensitivity of 85.1%, speciﬁcity of 100.0%, PPV of 100.0%,
and NPV of 88.9% at a threshold value of <1200 cell/μl.
Our ﬁndings, which indicated that proteinuria, could serve
as a better substitute marker for CD4 count is novel and
ﬁrst of its kind to be reported in a Ghanaian setting. In a
cross-sectional study by Atta et al. [26], proteinuria yielded
a sensitivity, speciﬁcity, and positive and negative predictive
values of 73%, 61%, 53%, and 79%, respectively, for HIVassociated nephropathy. An increased proteinuria depicts
decrease in glomerular ﬁltration threshold or renal failure.
This ﬁnding is also supported by the signiﬁcant association
between increased proteinuria and a decreased CD4 count
observed in our current study. HIV-infected individuals
with proteinuria ≥ 2++ were 4.30 times more likely to
report with CD4 count below 350cells/μl. Early diagnosis
of proteinuria among HIV-infected patients will aid early
detection of renal impairment, and this will form the basis
to start HAART. Initiation of HAART has been shown to
improve HIV-associated nephropathy [27].
In some studies, conducted by Obirikorang et al. [13]
and Wondimeneh et al. [14], TLC was found to be the

6
best substitute marker for predicting disease progression in
HIV treatment naïve individuals with CD4 count <200
cell/μl. In this study, TLC was found to be the secondbest substitute marker for predicting CD4 < 350 cell/μl.
The disparity in ﬁndings could be attributed to the diﬀerent CD4 count cutoﬀ used. The use of CD4 count <350
cell/μl is likely to enroll a majority of participants leading
to an increasing statistical power and sample size compared to using CD4 count <200 cell/μl. However, a
cross-sectional study by Kamya et al. [28] found conﬂicting reports. Kamya and colleagues observed a 100% PPV
but 32.0% NPV for TLC, which implied that TLC could
limit the detection of HIV patients who are symptomatic
with >1200 cell/μl. Meanwhile, a similar cross-sectional
study in Ghana by Obirikorang and Quaye [13] observed
a sensitivity of 72.2%, speciﬁcity of 100.0%, PPV of
100.0%, and NPV of 95.7% at cutoﬀ point < 1200cell/μl
in predicting CD4 count < 200 cell/μl. TLC was observed
as a better substitute for CD4 count in their study.
This study developed a combined marker comprising
TLC, proteinuria, hematuria, and leukocyturia using the
best cutoﬀ points, and this yielded a better diagnostic
accuracy (98.0%) and a good predictive performance
for identifying HIV patients with CD4 count < 350
cell/μl compared to the individual markers (Figure 1).
This ﬁnding is novel and has not been reported elsewhere. The 98.0% diagnostic accuracy of the combined
markers implied that only 2% will not need HAART.
The signiﬁcant associations of TLC, proteinuria, leukocyturia, and hematuria with CD4 count indicate that these
markers play a synergistic role in the pathophysiology of
HIV infections.
Although the ﬁndings of this study are novel, there
were some limitations. We were not able to measure urine
albumin-creatinine ratio to explain the signiﬁcance of the
proteinuria and how it relates to HIV-associated nephropathy (HIVAN). Despite our extensive eﬀort to rule out
confounding factors which may interfere with some dipstick ﬁndings like proteinuria, leukocyturia, and hematuria,
there may be possible unforeseen confounders which were
not controlled. However, we are conﬁdent in our ﬁndings
and for the ﬁrst time in Ghana, our study will be a baseline for further probing.

5. Conclusion
This study observed that proteinuria could serve as a noninvasive screening tool for predicting the severity of HIV infection. Meanwhile, a combination of total lymphocyte count,
leukocyturia, proteinuria, and hematuria levels could serve
as a substitute marker for CD4 count in resource-limited
communities. It is therefore incumbent on the clinician to
incorporate urine dipstick screening in routine HIV monitoring and management.
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